# Teriparatide

## Alvosteo inj 20mcg/80microliters 2.4mL

| TAH Drug Code      | [IALVO](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IALVO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Postmenopausal osteoporosis， High risk of fracture or have failed or are intolerant to other osteoporosis therapy. Osteoporosis， Primary or hypogonadal in men; at high risk for fracture or have failed or are intolerant to other osteoporosis therapy. Osteoporosis due to systemic glucocorticoid therapy (daily dose equivalent to ?5 mg prednisone)， High risk of osteoporosis-induced fractures， including individuals with a history of osteoporotic fractures， multiple fracture risk factors， or have failed or are intolerant to other osteoporosis treatments. |
| Dosing             | 20 mcg subcutaneous injection once daily in the thigh or abdomen. Patients are advised to supplement calcium and vitamin D if their daily intake is insufficient.                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Patients with known allergies to teriparatide or any of its excipients， including angioedema and anaphylaxis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Common Gastrointestinal: Nausea (8.5% to 14% ) Musculoskeletal: Arthralgia (10.1% ) Other: Pain (21.3% ) Serious Cardiovascular: Angina pectoris (2.5% )， Orthostatic hypotension (5% )， Syncope (2.6% ) Dermatologic: Calcinosis cutis Endocrine metabolic: Hypercalcemia (Transient， 6% to 11%; verified on consecutive measurements， 1% to 3% ) Immunologic: Anaphylaxis， Hypersensitivity reaction Musculoskeletal: Osteosarcoma Other: Angioedema                                                                                                                      |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

## Forteo 750mcg/3mL， 28dose

| TAH Drug Code      | [IFOR7](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IFOR7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Osteoporosis in postmenopausal women at high risk of fractures. Osteoporosis in men， either primary or secondary to hypogonadism， at high risk of fractures. Osteoporosis in both women and men induced by glucocorticoid treatment， with a high risk of fractures.                                                                                                                                                                                                                                                                                             |
| Dosing             | SC， 20 mcg once daily.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | FORTEO should not be used in patients who are allergic to teriparatide or any of its excipients. Allergic reactions include angioedema and anaphylaxis.                                                                                                                                                                                                                                                                                                                                                                                                            |
| Adverse Effects    | GI disturbances， asthenia， hypotension， arthralgia， leg cramps， dizziness， depression， insomnia， vertigo， rhinitis， cough， pharyngitis， dyspnea， rash， increased sweating， hypercalcemia. Cardiovascular: Hypotension， Syncope Dermatologic: Rash， Sweating symptom Endocrine metabolic: Hyperuricemia Gastrointestinal: Constipation， Diarrhea， Indigestion， Nausea， Vomiting Musculoskeletal: Arthralgia (10.1% )， Spasm (1% to 10% ) Neurologic: Asthenia， Dizziness Respiratory: Increasing frequency of cough， Pharyngitis， Rhinitis |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| More Info          | [UpToDate](https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                              |

